Natera (NTRA) announced the activation of the NRG Oncology trial, ARCHER, a randomized, phase III study in muscle-invasive bladder cancer. The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Natera’s personalized, tumor-informed molecular residual disease test, as a pre-specified secondary endpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Puneet Souda’s Buy Rating on Natera Driven by Promising Signatera Trial Results and Market Growth Potential
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Natera says IMvigor011 bladder cancer trial achieves positive results
- Natera Inc. Reports Strong Growth and Strategic Advances
- Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating